Impedimed Limited ( (IPDQF) ) has released its Q4 earnings. Here is a breakdown of the information Impedimed Limited presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ImpediMed Limited is a global medical technology company specializing in bioimpedance spectroscopy (BIS) technology for non-invasive clinical assessment and monitoring of fluid status and tissue composition, primarily targeting secondary lymphoedema in breast cancer patients. In its 2025 financial year, ImpediMed reported a 23% revenue growth, driven by increased sales of its SOZO® Digital Health Platform and expanded reimbursement coverage. The company also made strategic advancements, including a successful trial in heart failure applications and the introduction of SOZO Pro for broader clinical settings. Key financial highlights include a total revenue of $12.7 million, a 25% increase in SOZO-Core business revenue, and a reduction in operating cash expenditure by 16%. Looking forward, ImpediMed aims to accelerate revenue growth, expand reimbursement coverage, and achieve profitability through continued focus on sales execution and innovation.